Vancouver, British Columbia--(Newsfile Corp. - August 6, 2014) - Henry Ji, President & CEO of Sorrento Therapeutics explains the company's cancer treatment drug, Cynviloq and Resiniferatoxin, a drug candidate currently in clinical studies for the treatment of cancer pain.
If you cannot view the video above, please visit:
http://www.ceoclips.com/companies/Video-Interview-with-Henry-Ji-President-and-CEO-of-Sorrento-Therapeutics.html
About Sorrento Therapeutics (NASDAQ:SRNE)
Sorrento is advancing a pipeline of small molecules, antibodies and antibody drug conjugates (ADCs) for the treatment of cancer and its associated pain. Sorrento’s lead programs include a next-generation paclitaxel drug, Cynviloq, in final stages of clinical development, as well as a non-opiate pain therapeutic for terminal cancer patients in mid-stage clinical development, resiniferatoxin (RTX). Sorrento is also fueling its drug pipeline with a diverse library of fully functional monoclonal antibodies, complemented by a comprehensive ADC platform comprised of wholly-owned conjugation chemistry, linkers and toxic payloads. This preclinical pipeline is driven by Sorrento’s core G-MAB® technology, one of the largest and most diverse fully human antibody libraries in the industry and proprietary ADC technology. http://sorrentotherapeutics.com/
About CEO Clips:
CEO Clips is the largest library of publicly traded company CEO videos in the US and Canada. These 90 second video profiles broadcast on national TV and are distributed online on top financial portals including: Thomson Reuters, BNN.ca, MSN Money, Stockhouse.com, Canadian Business Journal, Germany’s Investor SMS, and 32 sites in Europe. They are also disseminated via a video news release to several financial portals including Globe Investor, OTC Markets, TMX Money, and The National Post.
BTV – Business Television/CEO Clip Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com
